FLT3 and acute myeloid leukemia: While there is not yet a clear best practice or guideline for utilizing TKIs as post-transplant maintenance therapy in patients with FLT3-ITD+AML, many studies have shown survival benefits with tolerable toxicity profiles and costs [18].